ral Register Notice: FDA’s Gastrointestinal Drugs Advisory Committee will meet 8/28, from 8 a.m. to 5 p.m. at the DoubleTree by Hilton Hotel Washington, DC/Silver Spring, The Ballrooms, 8727 Colesville Road, Silver Spring, MD. The committee will discuss the results from clinical trials of an Abbott Laboratories supplemental BLA for Humira (adalimumab) for reducing signs and symptoms, and achieving clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy. Contact Cindy Hong, (301) 796-9001. To view this notice, click here.
